Work

Dose-escalation in the picture : pharmacological and imaging studies in depression

Year: 2008
Type: other
Abstract: Burton's work The anatomy of melancholy * (first published in 1621) was a best-seller.1 It describes many aspects of the disease that we currently recognize as depression: 2 the sometimes difficult distinction of the illness melancholy (depression) from 'normal' sadness, pain or sorrow after misery in life, the relation between stressful life-events and the development of the illness, the interaction of life-events and coping styles to develop the illness or remain well, the clinical symptoms, the enormous impact of the illness on a depressed person's life, social dysfunction and the tendency of recurrence and chronicity. 1 Nowadays, MDD is one of the most prevalent and disabling illnesses in psychiatry, after ischemic heart disease the second most common cause of disability worldwide and expected to be the world's second cause of disability by 2030, behind HIV/AIDS.3 MDD is diagnosed by the occurrence of a cluster of different symptoms affecting mood, pleasure, attention, activities, vital somatic functions (eating, sleep), and (ruminative) thoughts over oneself, guilt or suicide over a prolonged period of time.For clinical and scientific uniformity, MDD is currently defined by criteria specified in the Diagnostic and Statistical Manual (4 th edition; DSM-IV), 4 which is a nontheoretical classification-system. *Melancholy is derived from the Greek Μελαγχολια (melancholia), which refers to the black choler (bile) that was seen as the material cause of the illness those days. ChapterChapter 1 1 16 start of a more aggressive treatment with increased side effects.Over the last decades, the time to declare that an antidepressant trial failed, increased from 3 weeks 71 to 6-8 weeks.70;72 Interestingly, recommendations on this lag-time were never derived from studies primarily designed to quantify the timing of the determination of response.Current guidelines for depression differentially recommend a minimal duration of antidepressant therapy between 4 and 6 weeks.13;21;23;25;26;28;29;67;73 At these time points ('critical decision points') 67 a next treatmentstrategy must be considered.A final dilemma is to adequately re-evaluate the diagnosis, without the (counter-) transference of helplessness.Critical decision points are important for the reassessment of somatic or psychiatric co-morbidity, re-evaluation of persistent psychosocial problems and treatment adherence.However, when none of these issues apply, the patient may be accused of 'a failure to cooperate', or blamed for the non-response by 'having a personality disorder' or 'not being motivated for treatment'.Although these reproaches occasionally may be justified, they could also indicate the patient's and/or clinician's helplessness, which is often transferred from a depressed person to the persons surrounding him or her.Most depressed patients want to improve, but are indeed disabled in their coping-styles, their motivation and their problem solving capacities.As such, routinely administered behavioural interventions (registration, planning and gradual reactivation) 74 are valuable in the pharmacological treatment of MDD, also deferring increased helplessness.† Single Photon Emission Computed Tomography (SPECT) and Positron Emission Tomography (PET) use a variety of radioligands with various half-lives to quantify different targets (transporters, receptors, or blood-flow or metabolism).Functional Magnetic Resonance Imaging (fMRI) is a technique to image brain activity (hemodynamic response) related to a specific task or stimulus.‡ Similar changes included increased metabolism in frontal, parietal and posterior cingulate, and decreased metabolism in subgenual cingulate gyrus.Distinct changes included no changes in subcortical brainstem, hippocampal, and caudate metabolism in placebo-responders.Chapter General introduction and outline 1 23When 'the miracle doesn't happen', 5 strategies for non-response are possible options: prolongation of the initial trial, dose-escalation, switching, augmentation and combination of antidepressants.For all these options the current evidence is either equivocal or fragmentary.In order to develop evidence based treatment algorithms for the 50% of MDD-patients who turn out to be non-responsive to the first antidepressant trial, systematic overviews of the literature are required and gaps in the evidence-base need to be addressed by new research-projects.More fundamentally, the perceived delayed onset of symptom improvement with antidepressants, their moderated efficacy, and their extensive effects in the brain beyond an increase in serotonergic or noradrenergic neurotransmission, summons the question what is the etiopathogenetic model for MDD.Or, more specifically, what is the evidence that corroborates the corner-stone of most antidepressant's action: the monoamine hypothesis and the involvement of the serotonergic system as a causal explanation for MDD. Research projects underlying this thesisThis thesis incorporates three research projects that were initiated and conducted by the Program for Mood Disorders of the Academic Medical Center (AMC).One additional project was initiated by the department of vascular medicine of the AMC.First, a guideline-project was initiated with a grant from the Academic Medical Center (No SFA.07.012).Aim of this guideline project was to develop an evidence based guideline for nonresponse after a first SSRI.Second, as a result of this guideline project, two grants were obtained from the Netherlands Organization for Health Research and Development (ZonMw), program Mental Health, education of investigators in mental health (Geestkracht-OOG; projects #100-002-001 and #100-002-002).These grants were applied to initiate the DELPHI-study (Dose-Escalation Legitimate?Pharmacology and Imaging studies in depression).The DELPHI-study was set up as a methodologically sound trial to study clinical effectiveness of dose-escalation as a strategy for non-response.As a novel extension to existent dose-escalation trials, we aimed to investigate the molecular neurobiological target of dose-escalation: the occupancy of the serotonin transporter (SERT) by paroxetine (a SSRI).This was done by the acquisition of two or three single photon emission computed tomography (SPECT) scans in a subgroup of drug-free patients of the total DELPHI-cohort.A third project was started as an extension to the DELPHI-SPECT study.This third project could be planned after a grant from the Dutch Brain Foundation (Hersenstichting) was obtained (project #14F06.45).The DELPHI-fMRI aimed to investigate the neurobiological changes in brain activation by treatment with paroxetine in a functional Magnetic Resonance Imaging (fMRI) study.This study was superimposed on the SPECT-imaging of the last 22 drug-free patients participating in DELPHI.The final fourth research project in this thesis was initiated after an almost fatal bleeding complication, which occurred in a patient who underwent surgery, and lost 12 litres of blood.This complication was afterwards attributed to fluoxetine use.This project was funded internally by mutual contributions of both participating AMC-departments. The questions addressed in this thesis1 Is a short, easy to use clinician rated questionnaires as effective and precise as the routine Hamilton depression rating scale (HDRS)?The HDRS 54 is most frequently used as the golden-standardin clinical trials, but is probably too extensive to use in clinical practice.61 To facilitate clinical measurements of depression severity and objectivity for critical decision points, we reanalyzed the treatment-outcomes of two antidepressant-psychotherapy trials, which were performed by the Mentrum research group.139;140 We therefore investigated whether the effect-sizes of two 6-item subscales of the HDRS (17-items) -the Maier 141 and Bech 59 subscales -were comparable to the original HDRS in the measurement of depression severity and the sensitivity to measure changes.Furthermore, we investigated whether this comparability was stable across the full range of Chapter Chapter 1 1 24 response to treatment, and across different treatments and for different baseline severity of depression.We also determined cut-off points for remission for these subscales compared to conventional HDRS definitions.66;142;143 See chapter 3.2 What is the evidence for dose-escalation as a strategy for non-response to a first SSRI?For this question, we performed a systematic review of the evidence for the dose response relationship for SSRIs in MDD.See chapter 4.3 What is the evidence for switching antidepressants as a strategy for non-response to a first SSRI?For this question, we performed a systematic review of the evidence for switching after failure of a first SSRI in MDD.Part of this study was a meta-analysis of three switch-studies.See chapter 5.4 Does the depletion of monoamine (5-HT and NA/DA) systems lower mood in humans, and is this lowering of mood different across different populations?For this question, we performed a systematic review of monoamine depletion studies reporting mood effects of depletion.As an extension of previous systematic reviews of monoamine depletion studies, [88][89][90][91][92][93] we aimed to pool the results ofthe small-sized depletion studies, because they might not have detected small differences by a lack of power, and pooling would quantify the balance of positive versus negative studies.Therefore, we applied a pooling technique (modified from conventional meta-analyses of randomized controlled trial data and including an adjustment for small sample bias) to handle the statistically paired cross-over designs of these studies in formal, stratified meta-analyses.144 See chapter 6.5 Do MDD-patients and healthy controls differ in the number of central serotonin transporters, and is the amount of available SERTs correlated with depression severity?Despite the fact that the working-mechanism of antidepressants supports t
Language: English
Field: Medicine
Open Access status: green
OpenAlex ID: W2119721082
Cites: 487
Cited by:
Related to: 10